Prestige Biopharma said Monday it would build a vaccine production center for Covid-19 and other infectious diseases.

The antibody-drug developer said it would break grounds for the vaccine center with the floor space of about 8,500 square meters separate from its second plant for antibody-drug production pushed by Prestige BioLogics. 

Prestige Biopharma will build a new vaccine production center by the end of this year.
Prestige Biopharma will build a new vaccine production center by the end of this year.

When completed, the vaccine center will have up to 100,000 liters' production capacity and proactively respond to manufacturing various infectious diseases, including the Covid-19 vaccine, the company said. Construction will begin this month and end by the end of this year. 

“The prolonged Covid-19 pandemic is increasing concerns about virus infections in the future while raising expectations about related vaccines,” Prestige Bio CEO Park So-yeon, said. “We expect to contribute to preventing future pandemics while securing a new engine for making profits.”

Copyright © KBR Unauthorized reproduction, redistribution prohibited